Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Judah Frommer
Morgan Stanley, Research Division

All right. Good afternoon, everyone. Thanks for being here. We’re very excited to have Jennifer and James from Trevi here with us for this session of Morgan Stanley Global Healthcare Conference.

I’m just going to go through a quick disclosure. For important disclosures, please visit www.morganstanley.com/researchdisclosures. With any questions, contact your institutional salesperson.

I’m Judah Frommer, one of the SMID biotech analyst here. And like I said, we’re very excited to have Trevi with us for this session. So maybe we’ll start off. It’s been a year of significant progress for Trevi. Before we dive in — maybe give the audience an intro of the company and your chronic cough programs from a high level?

Jennifer Good
Co-Founder, CEO, President, & Director

Sure. First of all, thank you for having us. We appreciate it. And thank you for those of you that have hung around till the end of the day to hear us. So Trevi is a simple story. We’re a single asset company focused in chronic cough indications. Three indications, idiopathic pulmonary fibrosis cough, other interstitial lung disease cough and refractory chronic cough. There’s been a lot of sort of movement on the competitive landscape around that. We have aligned with the FDA on our path forward and our lead indication of IPF cough. We’ve started those trials. We can get into more detail. So we are in Phase III, looking for a lot of data to start reading out some later this year and then second half of next year. So it’s been an exciting time to be in it. I’m joined by Jim